AbelsonTaylor for Astellas's AmBisome
Pharmaceutical Executive
When Astellas' AmBisome marketing campaign needed an upgrade to set it apart from the competition, AbelsonTaylor came up with a "fierce yet friendly" promotional tactic.
SMILING BEAR
AbelsonTaylor
BRAND AmBisome CLIENT Astellas FROM LEFT: Janet Kleve, creative director; Tim Brennan, senior art director; Donna Arey, senior copywriter; Lauren Cunningham, senior art director; Caren Spigland, senior copywriter
When Astellas' AmBisome marketing campaign needed an upgrade to set it apart from the competition, AbelsonTaylor came up with a "fierce yet friendly" promotional tactic. AmBisome was already viewed as a powerful way to combat invasive fungal infections, but the excellent safety of the drug compared to others' containing amphotericin B was often overlooked. AT's creative team devised a campaign that captured this quality in an eye-catching and effective display. The smiling bear translates AmBisome's brand essence from "power that's safer" to "friendlier power." This idea is also reflected in the bold and clever slogan: "Fierce on fungus. Kinder to kidneys."
Bright ideas don't always come easily, though. "We needed to communicate our position to the physician, and make sure the sales force was on board," says AT's Janet Kleve. "Since we were dealing with a serious disease state, we needed to weigh the tone of the branding and the promise of the product with physicians."
They made the grade. According to Kleve, physicians found the campaign memorable, and sales reps were ready and willing to use it.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
